EVOQUE Shows Feasibility in Transcatheter Mitral Valve Repair

News

EVOQUE Shows Feasibility in Transcatheter Mitral Valve Repair

Posted: 06/25/2020
Author:
Brian Forrestal, CRTonline.org

First-in-human results presented Thursday show that the novel transseptal EVOQUE transcatheter mitral valve replacement system is feasible, with high implant success, low complication rates and reduced mitral regurgitation (MR) at 30 days.

Most Viewed Pages

TARGET BP I: Alcohol-Mediated RDN Shows ‘Modest but Significant’ 24-Hour Ambulatory Systolic BP Drop vs. Sham Procedure at 3 Months

The DanGer Shock Trial & Panel Discussion

Coronary Sinus Reducer Relieves Angina, but Mechanism Remains Unclear: ORBITA-COSMIC Trial

Technology viewpoint: Evolution in PCI: The next major advance in implant technology to restore vessel function

Snaring, Entangling, Yanking, and Abandoning -- Horror Stories of Lost and Entrapped Gear

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

News

EVOQUE Shows Feasibility in Transcatheter Mitral Valve Repair

Most Viewed Pages

Explore the Site

Stay Connected